Jazz Inks $145 Million Settlement in Narcolepsy Drug Case (1)

Jazz Pharmaceuticals Plc said it will pay $145 million to resolve antitrust litigation accusing the company of colluding to delay the generic version of its brand-name narcolepsy drug Xyrem.

Jazz confirmed in a Securities and Exchange Commission filing that it made a preliminary deal with a class of indirect Xyrem buyers to settle claims that it paid Hikma Pharmaceuticals Plc to shelve generic versions of the drug as part of a reverse-payment deal.

Jazz hasn’t yet asked the court for preliminary approval of the deal and said in the SEC filing that it denies “all alleged wrongdoing.”

The proposed agreement ...